$1 billion Keytruda deal illustrates value of royalty right sales for research institutes
Transformative agreement shows why niche investment model may appeal to cash-strapped life sciences innovators
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.